Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects

References

• Offermanns S. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends Pharmacol Sci 2006; 27: 384–390
   PubMed Web of Science ®Google Scholar
• Carlson LA. Nicotinic acid: The broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005; 258: 94–114
   Web of Science ®Google Scholar
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–3421.
   Google Scholar
• Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583–1592
   PubMed Web of Science ®Google Scholar
• Capuzzi DM, Morgan JM, Brusco OA, Jr, Intenzo CM. Niacin dosing: Relationship to benefits and adverse effects. Curr Atheroscler Rep 2000; 2: 64–71
   PubMedGoogle Scholar
• Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Increasing HDL cholesterol with extended-release nicotinic acid: From promise to practice. Neth J Med 2004; 62: 229–234
   PubMed Web of Science ®Google Scholar
• Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): Efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol 1998; 82: 29U–34U
   PubMed Web of Science ®Google Scholar
• Mills E, Prousky J, Raskin G, Gagnier J, Rachlis B, Montori VM, Juurlink D. The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]. BMC Clin Pharmacol 2003; 3: 4
   PubMedGoogle Scholar
• Morrow JD, Awad JA, Oates JA, Roberts LJ. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol 1992; 98: 812–815
   PubMed Web of Science ®Google Scholar
• Morrow JD, Parsons WG, III, Roberts LJ. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 1989; 38: 263–274
   PubMedGoogle Scholar
• Phillips WS, Lightman SL. Is cutaneous flushing prostaglandin mediated?. Lancet 1981; 1: 754–756
   PubMed Web of Science ®Google Scholar
• Wilkin JK, Fortner G, Reinhardt LA, Flowers OV, Kilpatrick SJ, Streeter WC. Prostaglandins and nicotinate-provoked increase in cutaneous blood flow. Clin Pharmacol Ther 1985; 38: 273–277
   PubMed Web of Science ®Google Scholar
• Benyo Z, Gille A, Bennett CL, Clausen BE, Offermanns S. Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells. Mol Pharmacol 2006; 70: 1844–1849
   PubMed Web of Science ®Google Scholar
• Cheng K, Wu TJ, Wu KK, Sturino C, Metters K, Gottesdiener K, Wright SD, Wang Z, O'Neill G, Lai E, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci USA 2006; 103: 6682–6687
   PubMed Web of Science ®Google Scholar
• Maciejewski-Lenoir D, Richman JG, Hakak Y, Gaidarov I, Behan DP, Connolly DT. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J Invest Dermatol 2006; 126: 2637–2646
   PubMed Web of Science ®Google Scholar
• Lai E, De Lepeleire I, Crumley TM, Liu F, Wenning LA, Michiels N, Vets E, O'Neill G, Wagner JA, Gottesdiener K. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D-2 receptor subtype 1. Clin Pharmacol Ther 2007; 81: 849–857
   PubMed Web of Science ®Google Scholar
• Chang SW, Reddy V, Pereira T, Dean BJ, Xia YQ, Seto C, Franklin RB, Karanam BV. The pharmacokinetics and disposition of MK-0524, a prosglandin D2 receptor 1 antagonist, in rats, dogs and monkeys. Xenobiotica 2007; 37: 514–533
   PubMed Web of Science ®Google Scholar
• Levesque JF, Day SH, Chauret N, Seto C, Trimble L, Bateman KP, Silva JM, Berthelette C, Lachance N, Boyd M, et al. Metabolic activation of indole-containing prostaglandin D2 receptor 1 antagonists: Impacts of glutathione trapping and glucuronide conjugation on covalent binding. Bioorg Med Chem Lett 2007; 17: 3038–3043
   PubMed Web of Science ®Google Scholar
• Sturino CF, O'Neill G, Lachance N, Boyd M, Berthelette C, Labelle M, Li L, Roy B, Scheigetz J, Tsou N, et al. Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocy clopenta[b]indol-3-yl]-acetic acid (MK-0524). J Med Chem 2007; 50: 794–806
   PubMed Web of Science ®Google Scholar
• Paolini JF, Mitchel YB, Reyes R, Kher U, Lai E, Watson DJ, Norquist J, Meehan AG, Davidson M, Ballantyne CM, et al. Effects of the DP1-receptor antagonist MK-0524 on nicotinic acid-induced flushing in lipid clinic patients. Circulation 2006; 114: 318
   PubMedGoogle Scholar
• Paolini JF, Mitchel YB, Reyes R, Kher U, Lai E, Watson DJ, Norquist JM, Meehan AG, Bays HE, Davidson M, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008; 101: 625–630
   PubMed Web of Science ®Google Scholar
• Gresele P, Deckmyn H, Nenci GG, Vermylen J. Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. TiPS 1999; 12: 158–163
   Google Scholar
• Lai E, Wenning LA, Crumley TM, De Lepeleire I, Liu F, de Hoon JN, Van Hecken A, Depré M, Hilliard D, Greenberg H, et al. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist. Clin Pharmacol Ther 2008; 83: 840–847
   PubMed Web of Science ®Google Scholar
• Armstrong RA. Platelet prostanoid receptors. Pharmacol Ther 1996; 72: 171–191
   PubMed Web of Science ®Google Scholar
• Bode-Böger SM, Böger RH, Schubert M, Frölich JC. Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects. Eur J Clin Pharmacol 1998; 54: 707–714
   PubMedGoogle Scholar
• González-Correa JA, Arrebola MM, Martin-Salido E, Monoz-Marin J, Sánchez de la Cuesta F, De La Cruz JP. Effects of dexibuprofen of platelet function in humans–comparison with low-dose aspirin. Anesthesiology 2007; 106: 218–225
   PubMedGoogle Scholar
• McKenney J, Bays H, Koren MJ, Ballantyne C, Maccubbin D, Mitchel Y, Betteridge A, Kuznetsova O, Sapre A, Sisk CM, et al. Safety profile of extended release niacin/laropiprant in patients with dyslipidemia. J Am Coll Cardiol 2008; 51: A334
   Web of Science ®Google Scholar
• Lauring B, Dishy V, Luo W-L, Laterza O, Patterson J, Cote J, Chao A, Larson P, Gutierrez M, Wagner JA, et al. Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothomboxane B2, a marker of in vivo platelet function, in healthy hypercholesterolemic, and diabetic subjects. J Clin Pharm 2009; 49: 1426–1435
   PubMed Web of Science ®Google Scholar